April 30 (Reuters) - Genprex Inc GNPX.O:
GENPREX COLLABORATORS REPORT POSITIVE PRECLINICAL DATA ON THE USE OF REQORSA® GENE THERAPY FOR THE TREATMENT OF RAS INHIBITOR RESISTANT LUNG CANCER AT THE 2025 AACR ANNUAL MEETING
Source text: ID:nPn81HrV3a
Further company coverage: GNPX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.